Printer Friendly

PERSEPTIVE BIOSYSTEMS, INC.'S PROCESS DIVISION ANNOUNCES PILOT-SCALE SYSTEM MANUFACTURING AGREEMENT

 CAMBRIDGE, Mass., Nov. 23 ~PRNewswire~ -- The Process Division of PerSeptive Biosystems, Inc. (NASDAQ-NMS: PBIO) announced today that the company has entered into a manufacturing agreement with North Carolina SRT Inc. Under the terms of the agreement, the company acquired SRT's intellectual property and product rights relating to its skidmounted, pilot-scale chromatography system. SRT has also agreed to continue manufacturing these systems exclusively for PerSeptive Biosystems under contract. PerSeptive has begun to apply its expertise in automated chromatography systems and on-line monitoring of biopharmaceutical production to develop new computer software for these pilot-scale systems, which PerSeptive will market under the name AutoPilot(tm). PerSeptive intends to begin marketing AutoPilot during the next few months.
 Noubar B. Afeyan, Ph.D., president and CEO of PerSeptive, stated: "Many of our customers have indicated their interest in pilot-scale systems based on PerSeptive technologies. We have decided to enter into this business so that we can provide our process customers with a full and seamless line of equipment and media. Our customers currently develop and optimize purification processes using our proprietary POROS(R) media and the BioCAD(tm) workstation. Now, with the AutoPilot System, they can scale-up to kilogram sale production of their drugs rapidly."
 Daniel K. Freymeyer, vice president, process added, "After a review of options available to the company, we concluded that SRT offered superior hardware. The technology is proven and its pilot-scale systems have already been validated for the manufacture of biopharmaceuticals. The marriage of SRT's hardware with PerSeptive's expertise in chromatography and automation represents a powerful combination."
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required fo of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R), ImmunoDetection(tm) and Rational Surface Design(tm).
 Perfusion Chromatography and POROS(R) are registered trademarks and BioCAD(tm), ImmunoDetection(tm) and Rational Surface Design are trademarks of the company.
 -0- 11~23~92
 ~CONTACT: Robert A. Fein, vice president and chief financial officer of PerSeptive Biosystems, or Daniel K. Freymeyer II, vice president Process, PerSeptive Biosystems, Inc., 617-621-1787~
 (PBIO)


CO: PerSeptive Biosystems ST: Massachusetts IN: SU: PER

TM -- NE003 -- 0289 11~23~92 09:20 PST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 23, 1992
Words:375
Previous Article:ACUITY DIGITAL TO DEBUT FIRST OF ITS KIND MOBILE COMMUNICATIONS SERVICE IN SOUTHWESTERN MINNESOTA
Next Article:VANTAGE ANALYSIS SYSTEMS TO MERGE WITH VIEWLOGIC SYSTEMS
Topics:


Related Articles
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES INITIAL PUBLIC OFFERING OF 2.5 MILLION SHARES OF COMMON STOCK
PERSEPTIVE BIOSYSTEMS, INC., ANNOUNCES SETTLEMENT OF DISPUTE WITH FORMER PRESIDENT
ROBERT A. FEIN PROMOTED TO SENIOR VICE PRESIDENT, FINANCE FOR PERSEPTIVE BIOSYSTEMS
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES SECOND QUARTER RESULTS
PAUL J. SEKHRI JOINS PERSEPTIVE BIOSYSTEMS AS MARKETING DIRECTOR, ANALYTICAL PRODUCTS
PERSEPTIVE BIOSYSTEMS ANNOUNCES ELECTION OF DR. WILLIAM POUNDS TO ITS BOARD OF DIRECTORS
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES THE INTRODUCTION OF TWO NEW PERFUSION CHROMATOGRAPHY INSTRUMENTS
PERSEPTIVE BIOSYSTEMS AGREES TO ACQUIRE PERSEPTIVE TECHNOLOGIES II CORPORATION
PERSEPTIVE BIOSYSTEMS COMPLETES EXCHANGE OFFER FOR UNITS OF PERSEPTIVE TECHNOLOGIES II CORPORATION
Perseptive Biosystems Realizes $12.9 Million From Selling Portion of Stock in Millennium Pharmaceuticals

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters